Indeed, the coexistence of these outcomes (proliferation versus no cell fate decision) tentatively explain the less aggressive phenotype generally observed in FGFR3-mutated bladder carcinomas, in comparison with urothelial tumours over-expressing EGFR (associated only with a proliferative attractor). This evidence concerns the gene FGFR3 and urinary bladder carcinoma.